ArticleLancet regional health. Americas2026

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Brandi N Reeves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.